Clinical trials: Worm Infestation
Filariasis
Relative Bioavailability Study of Emodepside IR-tablets and Solution
This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov…
- Trial name
- NCT03383523
- Testing
- Emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Schistosomiasis
Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
This is a Phase 1, open-label, dose-escalation clinical trial to evaluate the safety, reactogenicity, and immunogenicity of the Sm-p80+GLA-SE vaccine candidate in healthy adults between 18 and 55 years of age.
- Trial name
- NCT05292391
- Testing
- Sm-p80, Sm-p80 + GLA-SE
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hookworm Infection, Hookworm Disease
Safety and Immunogenicity Study of Na-GST-1 With or Without CpG
Na-GST-1 is a protein expressed during the adult stage of the hookworm life cycle that is thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source.
- Trial name
- NCT02143518
- Testing
- Na-GST-1/Alhydrogel®, CpG 10104
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Schistosomiasis
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
The goal of this phase 1b, multicenter, randomized, placebo-controlled, observer-blinded, dose-escalation study is to assess the safety, tolerability, and immunogenicity of a three-dose regimen, spaced four weeks apart, given…
- Trial name
- NCT05762393
- Testing
- rSm-p80 + GLA-SE
- Where
- 2 sites in Burkina Faso, Madagascar
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Filariasis
Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside
The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in healthy male caucasian subjects.
- Trial name
- NCT03383614
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Hookworm Infections
Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
This study evaluates the efficacy, safety and immunogenicity of different formulations of the Na-GST-1 hookworm vaccine using a controlled human hookworm infection model in healthy, hookworm-naive adults.
- Trial name
- NCT03172975
- Testing
- Na-GST-1/Alhydrogel, Na-GST-1/Alhydrogel + CPG 10104, Na-GST-1/Alhydrogel + GLA-AF
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Hookworm Disease, Hookworm Infection
Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children
Double blind, randomized, controlled, dose-escalation Phase 1 clinical trial in hookworm-exposed children aged 6 to 10 years living in the area of Lambaréné, Gabon.
- Trial name
- NCT02839161
- Testing
- Na-GST-1/Alhydrogel, Na-APR-1 (M74)/Alhydrogel, Hepatitis B Vaccine
- Where
- Gabon
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Neurocysticercosis
Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole
The objectives of the Phase I study are to evaluate the safety and tolerance of increasing single oral doses of oxfendazole in healthy volunteers.The secondary objectives assess the pharmacokinetic profile of oxfendazole and…
- Trial name
- NCT02234570
- Testing
- Oxfendazole
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Schistosomiasis, Health Education
Health Education Model Led by Community Health Volunteers.
The goal of this intervention study is to investigate the level of knowledge, attitudes, and behaviors of students on schistosomiasis in Pemba Island.
- Trial name
- NCT06312462
- Testing
- health education
- Where
- Tanzania
- Volunteers
- 978 people, healthy volunteers welcome
- Sponsor
- Pemba Ministry of Health Zanzibar
Healthy Volunteers
First in Man Clinical Trial of Emodepside (BAY 44-4400)
This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers.
- Trial name
- NCT02661178
- Testing
- emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Hookworm Infection, Allergy
Development of a Skin Test for the Na-ASP-2 Hookworm Antigen
Na-ASP-2 is a protein expressed during the larval stage of the N. americanus hookworm life cycle. In a clinical study in previously hookworm-infected adults in Brazil, this protein induced urticarial reactions (rash) in a subset…
- Trial name
- NCT00603889
- Testing
- Na-ASP-2 Skin Test Reagent
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Helminthiasis
Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population
The purpose of the study is to compare the pharmacokinetic profiles of two Albendazole tablet formulations manufactured under the different granulation processes in healthy Chinese adult males.
- Trial name
- NCT01755637
- Testing
- Albendazole
- Where
- 2 sites in China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hookworm Infection
Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
Na-ASP-2 is a protein expressed during the larval stage of the N. americanus hookworm life cycle. In a clinical study in previously hookworm-infected adults in Brazil, this protein induced urticarial reactions (rash) in a subset…
- Trial name
- NCT00939198
- Testing
- Na-ASP-2 Skin Test Reagent
- Where
- Brazil
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Hookworm Infections
Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm
The rational of this study is to provide evidence on the safety and efficacy of a new chewable tablet of mebendazole compared to the standard tablet in preschool- and school-aged children infected with hookworm.
- Trial name
- CHEW_MEB_PEMBA (NCT03995680)
- Testing
- Mebendazole
- Where
- Tanzania
- Volunteers
- 397 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Hookworm Infection, Hookworm Disease
Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant
This study is designed to evaluate the safety, reactogenicity, and immunogenicity of Na-GST-1 adsorbed to Alhydrogel® with or without two different dose concentrations of a novel adjuvant, GLA-AF (1 µg or 5 μg) among healthy…
- Trial name
- NCT01385189
- Testing
- 10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Lymphatic Filariasis
Moxidectin for LF, Cote d'Ivoire (DOLF)
The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
- Trial name
- NCT04410406
- Testing
- Ivermectin, Diethylcarbamazine, Albendazole
- Where
- Côte d’Ivoire
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphatic Filariasis
Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi
Albendazole and ivermectin are currently used in combination for annual mass treatment of lymphatic filariasis in Africa. Although the drugs have been donated, the cost of such programmes is very high and has proven to be a major…
- Trial name
- FED (NCT01213576)
- Testing
- Albendazole 400mg and ivermectin 200mcg/kg, Albendazole and ivermectin, albendazole 800mg and ivermectin 400mcg/kg bi-annually
- Where
- Malawi
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Helminthic Infection
Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers
This Phase I study is an open label multiple ascending dose evaluation of the safety and PK of oxfendazole (3, 7.5, or 15 mg/kg) given orally daily to healthy adult men and nonpregnant women aged 18-45 followed by a single dose…
- Trial name
- NCT03035760
- Testing
- Oxfendazole
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Onchocerciasis
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in…
- Trial name
- NCT04311671
- Testing
- Moxidectin, Ivermectin, Albendazole
- Where
- 2 sites in Côte d’Ivoire, Democratic Republic of the Congo
- Volunteers
- 12,979 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Lymphatic Filariasis, Soil Transmitted Helminth Infections
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Approximately 3,500 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis endemic areas. The study will be performed in Indonesia in B. timori and W.
- Trial name
- DOLF-Indo (NCT01905423)
- Testing
- Albendazole (annual), Diethylcarbamazine (annual), Albendazole (semiannual)
- Where
- Indonesia
- Volunteers
- 17,108 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine